



Regulus Therapeutics Inc.  
Investor Relations Department  
10614 Science Center Dr  
San Diego, CA 92121  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: RGLS

Last Trade:	0.92
Trade Time:	4:00 PM ET Aug 23, 2017
Change:	0.06 <span style="color: green;">↑</span> (+6.826%)
Day Range	0.87 - 0.93
52-Week Range	0.79 - 3.65
Volume	843,951

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *microRNAs*. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced *microRNA* therapeutics pipeline complemented by a maturing *microMarkers*<sup>SM</sup> biomarkers platform and a rich intellectual property estate to retain its leadership in the *microRNA* field. Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting *microRNA*-122 for the tre... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Aug 8, 2017 [Regulus to Present at the 2017 Webbush PacGrow Healthcare Conference](#)
- Aug 1, 2017 [Regulus Reports Second Quarter 2017 Financial Results and Recent Events](#)
- Jul 25, 2017 [Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares](#)
- Jul 25, 2017 [Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017](#)
- Jul 19, 2017 [Regulus Announces Pricing of Public Offering of Common Stock](#)

## Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 3, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017 [Quarterly Report \(10-Q\)](#)
- May 5, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 2, 2016 [Quarterly Report \(10-Q\)](#)